Evidence map›Paper›PMID 42125699›Full record

ArticleFrontiers in oncology2026

Determinants of survival in patients treated with CPX-351 for acute myeloid leukemia.

Patrizia Chiusolo, Luana Fianchi, Filippo Frioni, Sabrina Giammarco, Elisabetta Metafuni, Maria Assunta Limongiello, Martina Quattrone, Marianna Criscuolo, Antonio Giordano, Simona Sica and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Patrizia Chiusolo *Section of Hematology, Department of Laboratory and Hematological Sciences, Catholic University, Rome, Italy.
Luana Fianchi *Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Filippo Frioni *Section of Hematology, Department of Laboratory and Hematological Sciences, Catholic University, Rome, Italy.
Sabrina GiammarcoFondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Elisabetta MetafuniFondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Maria Assunta LimongielloFondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Martina QuattroneSection of Hematology, Department of Laboratory and Hematological Sciences, Catholic University, Rome, Italy.
Marianna CriscuoloFondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Antonio GiordanoFondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Simona SicaSection of Hematology, Department of Laboratory and Hematological Sciences, Catholic University, Rome, Italy.
Livio PaganoSection of Hematology, Department of Laboratory and Hematological Sciences, Catholic University, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CPX-351 for the treatment of acute myeloid leukemia (AML) has demonstrated better efficacy compared with standard chemotherapy regimens, with an excellent safety profile. We aimed to assess the determinants of response, relapse, and survival in patients treated with CPX-351 as the first-line therapy for AML. In this retrospective monocentric study, we analyzed 60 consecutive patients treated with CPX-351 for therapy-related AML or AML with myelodysplastic-related changes. We observed a 61% overall response rate, with 58% complete response. The presence of complex karyotype at diagnosis predicted lower response rates. Among patients who achieved complete response, the relapse rate was 50%, with a median relapse-free survival of 154 days. The median overall survival was 412 days. We found that the biological profile at diagnosis is associated with survival. Leukocytosis at diagnosis, complex karyotype, and mutations of

Indexed as

acute myeloid leukemiacomplex karyotypeCPX-351HSCT, hematopoietic stem cell transplantleukocytosis

Identifiers

PMID42125699
PMCPMC13158078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.